PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 10, 2025Future Oncology2 citationsOpen Access

Community hematologist/oncologist perspectives on minimal residual disease testing in patients with multiple myeloma

View Full Paper
LGLucio N. GordanAWAmanda N. WarnerTHTrevor Heritage

Key Points

  • Community hematologists and oncologists report varied approaches to minimal residual disease testing in multiple myeloma.
  • Testing influences clinical decision-making, with emphasis on adapting treatment based on MRD results.
  • Barriers include access to MRD testing and understanding of clinical implications among patients and providers.
  • Patterns of MRD testing usage vary significantly across different healthcare practice settings.

Abstract

Aim To explore community hematologist/oncologist perspectives on the patterns, drivers, and barriers of use of minimal residual disease (MRD) testing in patients with multiple myeloma (MM), and gain understanding on the use of these test results in clinical decision-making and response-adapted treatment approaches.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Gordan et al. (2025) studied this question.

synapsesocial.com/papers/68c1cc3754b1d3bfb60f45d8https://doi.org/10.1080/14796694.2025.2546284
Ask AI
Helpful
Bookmark
Share
View Full Paper